

references

- 1 Cunningham G, et al. *Williams Obstetrics*. 21st ed. New York: McGraw-Hill Publishers; 2001.
- 2 Mayo Clinic (2012, December 4). Fetal development: The first trimester. Retrieved June 22, 2014, from <http://www.mayoclinic.org/healthy-living/pregnancy-week-by-week/in-depth/prenatal-care/art-20045302?footprints=mine>.
- 3 Gittenger-de-Groot, A. (2000). *Textbook of fetal cardiology: Normal and abnormal cardiac development*. (pp. 15-27). London: Greenwich Medical Media Limited.
- 4 deVries, J. (1982). The emergence of fetal behaviour. I. Qualitative aspects. *Early Hum Dev.*, 7(4), 301-22.
- 5 Licensed from The Endowment for Human Development. www.ehd.org.
- 6 Moore, K *Dermatoglyphics: Science in transition*. 1991; (pp. 95-112). New York: Wiley-Liss.
- 7 Hepper, P Sex differences in fetal mouth movements. *Lancet*. 1997;350(9094), 1820-21. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/9428256?dopt=Abstract>. Accessed January 30, 2014.
- 8 Glover, V., Fisk, N. Fetal pain: Implications for research and practice. *Br J Obstet Gynaecol*. 1999;106(9):881-86.
- 9 Mayo Clinic. (2012, Dec 04). *Fetal development: The first trimester*. Retrieved from <http://www.mayoclinic.org/prenatal-care/ART-20045302>. Accessed January 30, 2014.
- 10 Katz, V., et al. *Comprehensive Gynecology*. 5th ed. Philadelphia: Mosby-Elsevier; 2007.
- 11 Larimore, W.L. Growing debate about the abortifacient effect of the birth control pill and the principle of the double effect. *Journal Ethics and Medicine*. January 2000;16(1):23-30. Updated October 1, 2004. Available at: <http://www.epm.org/resources/2004/Oct/01/growing-debate-about-abortifacient-effect-birth-co/>. Accessed January 27, 2014.
- 12 Plan B One-Step™ drug summary. (2014). Retrieved from <http://www.pdr.net/drug-summary/plan-b-one-step?druglabelid=573&id=1542>. Accessed January 27, 2014.
- 13 *Important information about Plan B One-Step™: Side effects*. (2013). Retrieved from <http://www.planbonestep.com/taking-plan-b-one-step.aspx>. Accessed January 27, 2014.
- 14 *Important information about Plan B One-Step™: When not to take Plan B One-Step™*. (2013). Retrieved from <http://www.planbonestep.com/taking-plan-b-one-step.aspx>. Accessed January 27, 2014.
- 15 *Important information about Plan B One-Step™: Side effects*. (2013). Retrieved from <http://www.planbonestep.com/taking-plan-b-one-step.aspx>. Accessed January 27, 2014.
- 16 Raymond, E., Trussell, J. (2007). Population effect of increased access to emergency contraceptive pills: A systematic review. *Obstetrics & Gynecology*, 109(1), 181-88.
- 17 Trussell, J., Raymond, E., Cleland, K. (2013, December). *Emergency contraception: A last chance to prevent unintended pregnancy*. Retrieved from <http://ec.princeton.edu/questions/ec-review.pdf>. Accessed January 30, 2014.
- 18 Watson Pharma, Inc. (2013, Oct). *ella® full prescribing information: Use in specific populations*. Retrieved from http://pi.actavis.com/data_stream.asp?product_group=1699&p=pi&language=E. Accessed on January 30, 2014.
- 19 U.S. Food and Drug Administration. (2012). *FDA approved patient labeling: How effective is ella®?* Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022474s002lbl.pdf. Accessed January 30, 2014.
- 20 Larimore, W.L. Growing debate about the abortifacient effect of the birth control pill and the principle of the double effect. *Journal Ethics and Medicine*. January 2000;16(1):23-30. Updated October 1, 2004. Available at: <http://www.epm.org/resources/2004/Oct/01/growing-debate-about-abortifacient-effect-birth-co/>. Accessed January 27, 2014.
- 21 Harrison, D.J., Mitroka, J.G. Defining reality: The potential role of pharmacists in assessing the impact of progesterone receptor modulators and misoprostol in reproductive health. *The Annals of Pharmacotherapy*. Dec 21, 2010; 45(1):115-9.
- 22 U.S. Food and Drug Administration. (2012). *ella® full prescribing information: Use in specific populations*. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022474s002lbl.pdf. Accessed January 30, 2014.
- 23 U.S. Food and Drug Administration. (2012). *ella® full prescribing information: Adverse reactions*. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022474s002lbl.pdf. Accessed January 30, 2014.
- 24 U.S. Food and Drug Administration. (2012). *ella® full prescribing information: Drug interactions*. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022474s002lbl.pdf. Accessed January 30, 2014.

- 25 U.S. Food and Drug Administration. (2012). *ella* full prescribing information: Use in specific populations*. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022474s002lbl.pdf. Accessed January 30, 2014.
- 26.1 Chen, Q. (2011). Mifepristone in combination with prostaglandins for termination of 10-16 weeks' gestation: a systematic review. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 159, 247-254.85.
- 26.2 Boonstra, H. (2013). Medication abortion restrictions burden women and providers' and threaten U.S. trend toward very early abortion. *Guttmacher Policy Review*, 16(1). Retrieved from <http://www.guttmacher.org/pubs/gpr/16/1/gpr160118.html>. Accessed January 30, 2014.
- 27 U.S. Food and Drug Administration, Postmarket Drug Safety Information for Patients and Providers. (2011). *Mifeprex™(mifepristone) information*. Retrieved from website: <http://www.fda.gov/drugs/drugsafety/postmarketdrugafetyinformationforpatientsandproviders/ucm111323.htm>. Accessed January 30, 2014.
- 28 U.S. Food and Drug Administration, (2009). *Mifeprex™ medication guide (2957855)*. Retrieved from website: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM258412.pdf>. Accessed January 31, 2014.
- 29 Ibid.
- 30.1 U.S. Food and Drug Administration, Postmarket Drug Safety Information for Patients and Providers. (2010). *Mifeprex™ questions and answers: What serious adverse events have been reported after mifepristone use?* Retrieved from website: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111328.htm>. Accessed January 31, 2014.
- 30.2 Gacek, C. (2012). RU-486 (mifepristone) side-effects, 2000-2012. *Family Research Council Issue Analysis*.
- 31 U.S. Food and Drug Administration, Postmarket Drug Safety Information for Patients and Providers. (2011). *Mifeprex™ questions and answers: What is a ruptured ectopic pregnancy and how often does this happen?* Retrieved from website: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111328.htm>. Accessed January 31, 2014.
- 32.1 Spitz, I., Bardin, W., Benton, L., Robbins, A. (1998). Early pregnancy termination with mifepristone and misoprostol in the United States. *The New England Journal of Medicine*, 338(18), 1241-47. Retrieved from <http://www.nejm.org/doi/pdf/10.1056/NEJM199804303381801>. Accessed January 31, 2014.
- 32.2 Stubblefield, P., Carr-Ellis, S., Borgatta, L. (2004). Methods for induced abortion. *Obstetrics & Gynecology*, 104(1), 174-185. doi: 10.1097/01.AOG.0000130842.21897.53.
- 33 Ibid.
- 34 U.S. Food and Drug Administration, (2009). *Mifeprex™ medication guide (2957855)*. Retrieved from website: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM258412.pdf>. Accessed January 31, 2014.
- 35 U.S. Food and Drug Administration, (2005). *Mifeprex™ patient agreement*. Retrieved from website: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM258412.pdf>. Accessed January 31, 2014.
- 36.1 Physician's Desk Reference. (2014). *Methotrexate drug summary*. Retrieved from <http://www.pdr.net/drug-summary/methotrexate-injection-methotrexate-for-injection?druglabelid=764>. Accessed January 31, 2014.
- 36.2 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M. (2009). *Management of unintended and abnormal pregnancy comprehensive abortion care: Chapter 9 medical abortion in early pregnancy*. (1st ed., pp. 122-23). West Sussex: Wiley-Blackwell.
- 37.1 Physician's Desk Reference. (2014). *Cytotec (misoprostol) drug summary*. Retrieved from <http://www.pdr.net/drug-summary/cytotec?druglabelid=1044>. Accessed January 31, 2014.
- 37.2 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M. (2009). *Management of unintended and abnormal pregnancy comprehensive abortion care: Chapter 9 medical abortion in early pregnancy*. (1st ed., pp. 122-23). West Sussex: Wiley-Blackwell.
- 38.1 Katz, V., et al. *Comprehensive Gynecology*. 5th ed. Philadelphia: Mosby-Elsevier; 2007.
- 38.2 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M. (2009). *Management of unintended and abnormal pregnancy comprehensive abortion care: Chapter 10 first-trimester aspiration abortion*. (1st ed., pp. 135-51). West Sussex: Wiley-Blackwell.
- 38.3 American Congress of Obstetricians and Gynecologists. *Induced Abortion*. ACOG Patient Education Pamphlet; November 2008.
- 38.4 Rock, J., Thompson, J. *TeLinde's Operative Gynecology*. 8th ed. Philadelphia: Lippincott-Raven; 1997.
- 38.5 Stenchever, M.A., Droegemueller, W., Herbst, A.L., Mitchell, D. *Comprehensive Gynecology*. 4th ed. St. Louis: Mosby; 2001.
- 39 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M. (2009). *Management of unintended and abnormal pregnancy comprehensive abortion care: Chapter 11 dilation and evacuation*. (1st ed., pp. 157-74). West Sussex: Wiley-Blackwell.

- 40 Fox, M. (2007). Cervical preparation for second trimester surgical abortion prior to 20 weeks. *Contraception*, 76(6), 486-95.
- 41.1 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M. (2009). *Management of unintended and abnormal pregnancy comprehensive abortion care: Chapter 12 medical methods to induce abortion in the second trimester*. (1st ed., pp. 178-88). West Sussex: Wiley-Blackwell.
- 41.2 Pasquini, L., et al. Intracardiac injection of potassium chloride as method for fetocide: Experience from a single U.K. tertiary centre. *Br J Obstet Gynaecol*. 2008;115(4):528-31.
- 42 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M. (2009). *Management of unintended and abnormal pregnancy comprehensive abortion care: Chapter 11 dilation and evacuation*. (1st ed., pp. 157-74). West Sussex: Wiley-Blackwell.
- 43 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M.(2009). *Management of unintended and abnormal pregnancy comprehensive abortion care*. (1st ed., pp. 111-92). West Sussex: Wiley-Blackwell.
- 44.1 Katz, V., et al. *Comprehensive Gynecology*. 5th ed. Philadelphia: Mosby-Elsevier; 2007.
- 44.2 American Congress of Obstetricians and Gynecologists. *Induced Abortion. Patient Education Pamphlet*; November 2008.
- 45 Lohr, P. (2011). Clinical Update: Very early surgical abortion. Retrieved August 10, 2015, from [http://www.abortioireview.org/index.php/site/article/958/ Issue 34](http://www.abortioireview.org/index.php/site/article/958/Issue%2034).
- 46.1 Katz, V., et al. *Comprehensive Gynecology*. 5th ed. Philadelphia: Mosby-Elsevier; 2007.
- 46.2 American Congress of Obstetricians and Gynecologists. Antibiotic prophylaxis for gynecologic procedures. *Practice Bulletin No. 104*; May 2009.
- 46.3 American Congress of Obstetricians and Gynecologists. *Dilatation & Curettage. Patient Education Pamphlet*; December 2005.
- 46.4 American Congress of Obstetricians and Gynecologists. *Pelvic Inflammatory Disease. Patient Education Pamphlet*; April 2010.
- 47.1 Katz, V., et al. *Comprehensive Gynecology*. 5th ed. Philadelphia: Mosby-Elsevier; 2007.
- 47.2 American Congress of Obstetricians and Gynecologists. *Induced Abortion. Patient Education Pamphlet*; November 2008.
- 47.3 American Congress of Obstetricians and Gynecologists. *Dilatation & Curettage. Patient Education Pamphlet*; December 2005.
- 48 Guttmacher Institute. State policies in brief, abortion reporting requirements as of January 2014. Available at: http://www.guttmacher.org/statecenter/spibs/spib_ARR.pdf. Accessed January 31, 2014.
- 49 Katz, V., et al. *Comprehensive Gynecology*. 5th ed. Philadelphia: Mosby-Elsevier; 2007.
- 50 American Congress of Obstetricians and Gynecologists. Management of alloimmunization during pregnancy. *Practice Bulletin No. 75*; August 2006.
- 51.1 Katz, V., et al. *Comprehensive Gynecology*. 5th ed. Philadelphia: Mosby-Elsevier; 2007.
- 51.2 Paul, M., Lichtenberg, S., Borgatta, L., Grimes, D., Stubblefield, P., Creinin, M.(2009). *Management of unintended and abnormal pregnancy comprehensive abortion care*. (1st ed., pp. 111-92). West Sussex: Wiley-Blackwell.
- 52 Guttmacher Institute. (2013, December). *Facts on induced abortion in the United States*. Retrieved from http://www.guttmacher.org/pubs/fb_induced_abortion.pdf. Accessed February 1, 2014.
- 53 Thorp, J.M., Hartmann, K.E., Shadigian, E. Long-term physical and psychological health consequences of induced abortion: Review of the evidence. *Obstet Gynecol Surv*. 2003;58(1):67-79.
- 54.1 Guttmacher Institute. State policies in brief, abortion reporting requirements as of January 2014. Available at: http://www.guttmacher.org/statecenter/spibs/spib_ARR.pdf. Accessed January 31, 2014.
- 54.2 Pazol, K., et al. Centers for Disease Control and Prevention. *Abortion Surveillance - United States, 2007. Morbidity and Mortality Weekly Report. Surveillance Summaries*. February 25, 2011;60(01):1-39.
- 55.1 Swingle, H. M., Colaiza, T. T., Zimmerman, M. B., Morriss, F. H. (2009). Abortion and the risk of subsequent preterm birth: A systematic review with meta-analyses. *The Journal of Reproductive Medicine*, 54(2), 95-108.
- 55.2 Shah, P. S., Zao, J. (2009). Induced termination of pregnancy and low birthweight and preterm birth: A systematic review and meta-analyses. *British Journal of Obstetrics & Gynaecology*, 116(11), 1425-42. doi: 10.1111/j.1471-0528.2009.02278.x.
- 55.3 Moreau, C., Kaminski, M., Ancel, P.Y., Bouyer, J., et al. Previous induced abortions and the risk of very preterm delivery: Results of the EPIPAGE study. *Br J Obstet Gynaecol*. 2005;112(4):430-37.
- 55.4 Ancel, P.Y., Lelong, N., Papiernik, E., Saurel-Cubizolles, M.J., Kaminski, M. History of induced abortion as a risk factor for preterm birth in European countries: Results of EUROPOP survey. *Hum Reprod*. 2004;19(3):734-40.

- 55.5 Behrman, R., Stith, B. Preterm birth: Causes, consequences, and prevention. *Institute of Medicine of the National Academy of Sciences*; 2006.
- 56.1 Ibid.
- 56.2 Rooney, B., Calhoun, B. Induced abortion and risk of later premature births. *J Am Phys Surg*. 2003;8(2):46-49.
- 57.1 Troisi, R., et al. (2013). A linked-registry study of gestational factors and subsequent breast cancer risk in the mother. *Cancer Epidemiol. Biomarkers Prev*, 22(5), 835-47.
- 57.2 National Institutes of Health, *National Cancer Institute*. (2012). *Breast cancer risk in American women*. Retrieved from website: <http://www.cancer.gov/cancertopics/factsheet/detection/probability-breast-cancer>. Accessed February 1, 2014.
- 57.3 Trichopoulos, D. (1983). Age at any birth and breast cancer risk. *Int. J. Cancer*, 31, 701-04.
- 57.4 Vatten, L., et al. (2002). Pregnancy related protection against breast cancer depends on length of gestation. *Brit J of Cancer*. 87, 289-90.
- 58 Ibid.
- 59.1 Hsieh, C., et al. Delivery of premature newborns and maternal breast cancer risk. *Lancet*. 1999.
- 59.2 Russo, J., et al. Developmental, molecular and cellular basis of human breast cancer. *J Natl Cancer Inst Monogr*. 2000;27:17-37.
- 60.1 Bhadoria, A.S., Kapil, U., Sareen, N., Singh, P. (2013). Reproductive factors and breast cancer: A case-control study in tertiary care hospital of north India. *Indian Journal of Cancer*, 50, 316-21. doi: 10.4103/0019-509X.123606
- 60.2 Huang, Y., Zhang, X., Song, F., Dai, H., Wang, J., Gao, Y. (2014). A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. *Cancer Causes & Control*, 25(2), 227-36. Retrieved from <http://link.springer.com/article/10.1007/s10552-013-0325-7>. Accessed February 1, 2014.
- 60.3 Brind, J. Induced abortion as an independent risk factor for breast cancer: A critical review of recent studies based on prospective data. *J Am Phys Surg*. Winter 2005;10(4).
- 60.4 Carroll, P. The breast cancer epidemic: Modeling and forecasts based on abortion and other risk factors. *J Am Phys Surg*. 2007;12(3).
- 61.1 Lowit, A., Bhattacharya, S., & Bhattacharya, S. (2010). Obstetric performance following an induced abortion. *Best Practice & Research in Clinical Obstetrics & Gynaecology*, 24(5), 667-82. doi:10.1016/j.bpobgyn.2010.02.015
- 61.2 Hung, T., Hsieh, C., Hsu, J., Chiu, T., Lo, L., & Hsieh, T. (2007). Risk factors for placenta previa in an Asian population. *International Journal of Gynecology & Obstetrics*, 97(1), 26-30. doi:10.1016/j.ijgo.2006.12.006.
- 61.3 Johnson, L. G., Mueller, B. A., & Daling, J. R. (2003). The relationship of placenta previa and history of induced abortion. *International Journal of Gynecology & Obstetrics*, 81(2), 191-8. doi:10.1016/S0020-7292(03)00004-3.
- 61.4 Tuzoviae, L., & Ilijic, M. (2003). Obstetric Risk Factors Associated with Placenta Previa Development: Case-Control Study. *Croat Med J*, 44(6), 728-33.
- 61.5 Faiz, A. S., & Ananth, C. V. (2003). Etiology and risk factors for placenta previa: an overview and meta-analysis of observational studies. *Journal of Maternal-fetal & Neonatal Medicine*, 13(3), 175-90. doi:10.1080/713605832.
- 61.6 Ananth, C., Smulian, J., & Vintzileos, A. (1997). The association of placenta previa with history of cesarean delivery and abortion: a metaanalysis. *Am J Obstet Gynecol*, 177(5), 1071-8.
- 61.7 Taylor, V. M., & Kramer, M. D. (1993). Placental previa in relation to induced and spontaneous abortion: a population-based study. *Obstet Gynecol*, 82(1), 88-91.
- 61.8 Ananth, C. V., Smulian, J. C., & Vintzileos, A. M. (2003). The effect of placenta previa on neonatal mortality: A population-based study in the United States, 1989 through 1997. *American Journal of Obstetrics and Gynecology*, 188(5), 1299-304. doi:10.1067/mob.2003.76.
- 61.9 Sheiner, E., Shoham-Vardi, I., Hallak, M., Hershkowitz, R., Katz, M., & Mazor, M. (2001). Placenta previa: obstetric risk factors and pregnancy outcome. *Journal of Maternal-fetal & Neonatal Medicine*, 10(6), 414-9. doi:10.1080/714052784.
- Tuzoviae, L., & Ilijic, M. (2003). Obstetric Risk Factors Associated with Placenta Previa Development: Case-Control Study. *Croat Med J*, 44(6), 728-33.
- 62.1 Coleman, P.K. (2011). Abortion and mental health: Quantitative synthesis and analysis of research published 1995-2009. *The British Journal of Psychiatry*, 199, 180-86. doi: 10.1192/bjp.bp.110.077230.
- 62.2 Thorp, J.M., Hartmann, K.E., Shadigian, E. Long-term physical and psychological health consequences of induced abortion: Review of the evidence. *Obstet Gynecol Surv*. 2003;58(1):67-79.
- 63.1 Cogle, J.R., et al. Depression associated with abortion and childbirth: A long-term analysis of the NLSY cohort. *Med Sci Monit*. 2003;9(4):105-12.
- 63.2 Fergusson, D.M., et al. Abortion in young women and subsequent mental health. *J Child Psychol Psychiatry*. 2006;47(1):16-24.

- 63.3 Pedersen, W. Abortion and depression: A population-based longitudinal study of young women. *Scand J Public Health*. 2008;36(4):424-28.
- 63.4 Rees, D.I., Sabia, J.J. The relationship between abortion and depression: New evidence from the Fragile Families and Child Wellbeing Study. *Med Sci Monit*. 2007;13(10):430-36.
- 64.1 Fergusson, D.M., et al. Abortion in young women and subsequent mental health. *J Child Psychol Psychiatry*. 2006;47(1):16-24.
- 64.2 Coleman, P.K., Reardon, D., Rue, V. Prior history of induced abortion in relation to substance use during subsequent pregnancies carried to term. *Am J Obstet Gynecol*. 2002;187:1673-78.
- 64.3 Coleman, P.K., et al. Substance use among pregnant women in the context of previous reproductive loss and desire for current pregnancy. *Br J Health Psychol*. 2005;10:255-68.
- 64.4 Coleman, P.K. Resolution of unwanted pregnancy during adolescence through abortion versus childbirth: Individual and family predictors and psychological consequences. *J Youth Adolesc*. 2006;35:903-11.
- 64.5 Pedersen, W. Childbirth, abortion and subsequent substance use in young women: A population-based longitudinal study. *Addiction*. 2007 December;102(12):1971-78.
- 64.6 Reardon, D.C., Coleman, P.K., Cogle, J. Substance use associated with prior history of abortion and unintended birth: A national cross sectional cohort study. *Am J Drug Alcohol Abuse*. 2004;26:369-83.
- 65.1 Curley, M., Johnston, C. (2013). The characteristics and severity of psychological distress after abortion among university students. *The Journal of Behavioral Health Services & Research*, doi: 10.1007/s11414-013-9328-0.
- 65.2 Coleman, P.K., Coyle, C., Rue, V. (2010). Late-term elective abortion and susceptibility to posttraumatic stress symptoms. *Journal of Pregnancy*, Retrieved from <http://dx.doi.org/10.1155/2010/130519>. Accessed February 1, 2014.
- 65.3 Thorp, J.M., Hartmann, K.E., Shadigian, E. Long-term physical and psychological health consequences of induced abortion: Review of the evidence. *Obstet Gynecol Surv*. 2003;58(1):67-79.
- 65.4 Rue, V.M., et al. Induced abortion and traumatic stress: A preliminary comparison of American and Russian women. *Med Sci Monit*. 2004;10:5-16.
- 66.1 Fergusson, D.M., et al. Abortion in young women and subsequent mental health. *J Child Psychol Psychiatry*. 2006;47(1):16-24.
- 66.2 Reardon, D.C., Shuping, M.W., et al. Deaths associated with abortion compared to childbirth: A review of old and new data and the medical and legal implications. *J Contemp Health Law Policy*. 2004;20(2):279-327.
- 66.3 Gissler, M., et al. Injury deaths, suicides and homicides associated with pregnancy; *Eur J Public Health*. 2005;15(5):459-63.
- 66.4 Shadigian, E.M., et al. Pregnancy-associated death: A qualitative systematic review of homicide and suicide. *Obstet Gynecol Surv* 2005;60(3):183.
- 67.1 Coleman, P.K. Resolution of unwanted pregnancy during adolescence through abortion versus childbirth: Individual and family predictors and psychological consequences. *J Youth Adolesc*. 2006;35:903-11.
- 67.2 Reardon, D.C., Coleman, P.K., Cogle, J. Substance use associated with prior history of abortion and unintended birth: A national cross sectional cohort study. *Am J Drug Alcohol Abuse*. 2004;26:369-83.
- 67.3 Broen, A.N., Moum, T., Bodtger, A.S., Ekeberg, O. Psychological impact on women of miscarriage versus induced abortion: A two-year follow-up study. *Psychosom Med*. 2004;66(2):265-71.
- 67.4 Broen, A.N., Moum, T., Bodtger, A.S., Ekeberg, O. The course of mental health after miscarriage and induced abortion: A longitudinal, five-year follow-up study. *BMC Med*. 2005;3:18.
- 68 Coleman, P.K., Rue, V.M., Coyle, C.T. Induced abortion and intimate relationship quality in the Chicago Health and Social Life Survey. *Public Health*. April 2009;123(4):331-38.
- 69 Coleman, P.K., et al. Predictors and correlates of abortion in the Fragile Families and Well-Being Study: Paternal behavior, substance use, and partner violence. *Int J Ment Health Addict*. July 2009;7(3):405-22.
- 70 National Council for Adoption. Adoption awareness training program; 2009. Retrieved from website: <https://www.adoptioncouncil.org/publications/adoption-factbook.html>. Accessed February 1, 2014.
- 71 National Institutes of Health, National Library of Medicine. (2014). *Medline plus medical dictionary*. Retrieved from Merriam-Webster website: <http://www.nlm.nih.gov/medlineplus/medlineplusdictionary.html>. Accessed February 2, 2014.
- 72.1 Boonstra, H. (2013). Medication abortion restrictions burden women and providers' and threaten U.S. trend toward very early abortion. *Guttmacher Policy Review*, 16(1). Retrieved from <http://www.guttmacher.org/pubs/gpr/16/1/gpr160118.html>. Accessed January 30, 2014.
- 72.2 U.S. Food & Drug Administration. Truthful prescription drug advertising and promotion: The prescriber's role - recognize and report. Common violations. April 2010. Available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/PrescriptionDrugAdvertisingandPromotionalLabeling/UCM209847.pdf>. Accessed March 16, 2011.